Direct Thrombin Inhibitor Resistance and Possible Mechanisms
نویسندگان
چکیده
منابع مشابه
Ximelagatran: Direct Thrombin Inhibitor
Warfarin sodium is an effective oral anticoagulant drug. However, warfarin has a narrow therapeutic window with significant risks of hemorrhage at therapeutic concentrations. Dosing is difficult and requires frequent monitoring. New oral anticoagulant agents are required to improve current anticoagulant therapy. Furthermore, while warfarin is effective in venous disease, it does not provide mor...
متن کاملThe direct thrombin inhibitor hirudin.
This review discusses the pharmacology and clinical applications of hirudin, a bivalent direct thrombin inhibitor (DTI). Besides the current major indication for hirudin--anticoagulation of patients with heparin-induced thrombocytopenia (HIT)--the experience with hirudin in other indications, especially acute coronary syndromes, are briefly presented. Hirudins have been formally studied prior t...
متن کاملThe direct thrombin inhibitor melagatran/ximelagatran.
Melagatran is a synthetic, small-peptide direct thrombin inhibitor with anticoagulant activity. Ximelagatran, an oral prodrug, undergoes rapid enzymatic conversion to melagatran. Melagatran has rapid onset of action, fixed twice-daily dosing, stable absorption, apparent low potential for medication interactions, and no requirement for monitoring drug levels or dose adjustment. There is no speci...
متن کاملXimelagatran-an oral direct thrombin inhibitor.
OBJECTIVE To present the chemistry, pharmacology, and pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor (DTI), and to review available comparative clinical trial data evaluating its efficacy and safety relative to other antithrombotic agents in the prevention and treatment of thromboembolism. DATA SOURCES A search of the PubMed and Cochrane databases (1995-August 2004), supp...
متن کاملDRUG EVALUATION Dabigatran etexilate: an oral direct thrombin inhibitor
10.2217/14750708.5.5.685 © 2 Dabigatran etexilate is a direct thrombin inhibitor that offers potential advantages over existing anticoagulants for the prevention and treatment of venous and arterial thrombosis. It is administered orally, has a rapid onset of action, a predictable anticoagulant effect and does not require laboratory monitoring. Trial results indicate that dabigatran etexilate ha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hospital Pharmacy
سال: 2016
ISSN: 0018-5787,1945-1253
DOI: 10.1310/hpj5111-922